ACTU ACTUATE THERAPEUTICS, INC.

Nasdaq actuatetherapeutics.com


$ 5.99 $ 0.00 (0 %)    

Friday, 21-Nov-2025 10:11:54 EST
QQQ $ 584.55 $ -2.78 (-0.47 %)
DIA $ 460.39 $ 0.92 (0.2 %)
SPY $ 653.92 $ -1.13 (-0.17 %)
TLT $ 89.49 $ -0.17 (-0.18 %)
GLD $ 374.17 $ 0.18 (0.05 %)
$ 6.09
$ 6.08
$ 5.75 x 100
$ 6.25 x 1,111
-- - --
$ 5.47 - $ 11.99
208,376
na
141.55M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 09-24-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of ...

Core News & Articles

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current ...

Core News & Articles

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Core News & Articles

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Core News & Articles

-SEC Filing

Core News & Articles

B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and an...

Core News & Articles

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

Core News & Articles

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION